Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
monoclonal antibody under investigation for the treatment of non-Hodgkin's lymphoma.
Etymologies
from Wiktionary, Creative Commons Attribution/Share-Alike License
Support
Help support Wordnik (and make this page ad-free) by adopting the word veltuzumab.
Examples
-
Substantial improvement in therapeutic activity was observed when veltuzumab was included.
Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer Therapy - Yahoo! Finance 2010
-
In vivo studies also examined combination therapy using the ADC and veltuzumab.
Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer Therapy - Yahoo! Finance 2010
-
Additionally, in a subcutaneous lymphoma model in mice, median survival time (MST) for untreated animals was only 7 days, while the tumor-specific epratuzumab-SN-38 conjugate in combination with veltuzumab increased MST 10-fold to more than 77 days.
-
In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.
-
Additionally, in a subcutaneous lymphoma model in mice, median survival time (MST) for untreated animals was only 7 days, while the tumor-specific epratuzumab-SN-38 conjugate in combination with veltuzumab increased MST 10-fold to more than 77 days.
-
In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.
-
Additionally, in a subcutaneous lymphoma model in mice, median survival time (MST) for untreated animals was only 7 days, while the tumor-specific epratuzumab-SN-38 conjugate in combination with veltuzumab increased MST 10-fold to more than 77 days.
-
Additionally, in a subcutaneous lymphoma model in mice, median survival time (MST) for untreated animals was only 7 days, while the tumor-specific epratuzumab-SN-38 conjugate in combination with veltuzumab increased MST 10-fold to more than 77 days.
-
In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.
-
In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.